Clinical Trials Browser

ruxolitinib × CNS × Clear all

Glioblastoma, Glioma

NCT06991101 2025-12-26

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Phase 2 Recruiting

190 enrolled

CNS

Brain Neoplasms, Glioblastoma

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

Clinical Trials

Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies